Are Indian Biotech Companies Leading the Charge in mRNA-Based Vaccines and Therapeutics?
Click to start listening
Synopsis
Discover how Indian biotech companies are pioneering the development of mRNA-based vaccines and therapeutics, driven by the BioE3 policy. Experts share insights on challenges, advancements, and the future of biomanufacturing in this transformative sector.
Key Takeaways
- Indian biotech firms are advancing mRNA-based vaccines and therapeutics.
- The BioE3 Policy aims to position India as a leader in bio-based innovations.
- Challenges in the sector include product delivery and raw material dependence.
- mRNA therapies have the potential to address a wide range of diseases.
- Webinars provide a collaborative platform for industry experts and researchers.
New Delhi, May 17 (NationPress) Indian biotech firms are making significant strides in the development of mRNA-based vaccines and therapeutics, as reported by a team of scientists from the Department of Biotechnology (DBT), which operates under the Ministry of Science and Technology.
This statement was made during the 14th Webinar in the ‘Webinar Series on Biofoundry and Biomanufacturing Initiative’, in collaboration with the Biotechnology Industry Research Assistance Council (BIRAC).
The focus of the session was on “Biomanufacturing for mRNA Therapeutics”, a crucial aspect of the BioE3 (Biotechnology for Economy, Environment and Employment) Policy.
According to Dr. Alka Sharma, Senior Adviser/Sc ‘H’ at DBT, “The vision of the BioE3 Policy is to promote high-performance biomanufacturing by endorsing sustainable green growth. This initiative signifies a global transition towards sustainability, igniting a ‘BioRevolution’ that has the potential to transform economies and societies.”
She noted that the 14th Webinar concentrated on mRNA therapeutics, a significant thematic subsector within the policy.
“Numerous Indian biotech companies and research institutions are deeply engaged in the creation of mRNA-based vaccines and therapeutics,” Sharma remarked, while also addressing certain hurdles facing the sector, such as product delivery, product stability, and import dependence for raw materials.
The BioE3 Policy, sanctioned by the Union Cabinet and unveiled by the Minister of Science and Technology, seeks to establish India as a global frontrunner in bio-based innovations.
This policy emphasizes the advancement of sustainable biomanufacturing across various thematic areas, including Precision Therapeutics like mRNA therapeutics, thereby supporting economic development and ensuring affordable healthcare for the Indian populace.
Dr. Varshneya Singh, Scientist ‘D’ at DBT, offered a detailed overview of the mRNA therapeutics subsector.
“mRNA-based therapies signify a revolutionary breakthrough in biotechnology, capable of addressing a wide array of diseases, including cancer, genetic disorders, and infectious diseases,” Singh noted.
He presented a SWOT analysis of the subsector, outlining its strengths, weaknesses, opportunities, and threats.
Dr. Raghavan Varadarajan from IISc Bangalore delved into pioneering advancements in mRNA-LNP vaccine technology, highlighting its transformative impact on modern medicine.
He discussed the mRNA vaccine design process, the significant advantages of the mRNA vaccine approach, key structural elements of mRNA, the procedure for LNP preparation, a comparative analysis of various mRNA-LNP formulations, the types of microfluidic chips used, and a comparison of different formulation methods.
This Webinar served as a collective platform, uniting academia, industry specialists, start-ups, and researchers to examine the latest advancements and emerging prospects in the domain of mRNA therapeutics biomanufacturing.
Point of View
It is crucial to recognize the pivotal role that the BioE3 Policy plays in positioning India as a leader in biotechnology. The proactive approach of Indian biotech firms in developing mRNA-based solutions could significantly impact healthcare accessibility and affordability, while also addressing global challenges in disease management. This commitment to innovation and sustainability aligns with the nation's broader goals for economic growth and public health.
NationPress
25/07/2025
Frequently Asked Questions
What is the BioE3 Policy?
The BioE3 Policy, approved by the Union Cabinet, aims to promote high-performance biomanufacturing in India, ensuring sustainable growth and positioning the country as a leader in bio-based innovations.
What are mRNA-based therapies?
mRNA-based therapies represent a groundbreaking advancement in biotechnology, designed to treat various diseases, including cancer, genetic disorders, and infectious diseases.
What challenges does the Indian biotech sector face?
Key challenges include product delivery, product stability, and dependence on imports for raw materials, which need to be addressed to enhance the sector's growth.
How does the DBT support biotech companies?
The Department of Biotechnology (DBT) supports biotech companies through initiatives like the BioE3 Policy, funding, and collaborative platforms such as webinars.
What is the significance of mRNA-LNP vaccine technology?
mRNA-LNP vaccine technology is considered revolutionary in modern medicine, offering significant advantages in vaccine design and efficacy.
